The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Adalimumab (Humira) and Biosimilar Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2029
Synopsis
The global Adalimumab (Humira) and Biosimilar market size was valued at USD 23070 million in 2022 and is forecast to a readjusted size of USD 16210 million by 2029 with a CAGR of -4.9% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The expiration of patents for adalimumab (Humira) has emerged as a significant driver in the biosimilar market. Adalimumab is a widely used biologic medication for autoimmune diseases. The patent expiry allows for the entry of biosimilar versions of Humira, which are highly similar and offer a more cost-effective alternative. This increased competition fosters price reduction and improved accessibility for patients, addressing the growing demand for affordable treatments. Furthermore, regulatory support for biosimilars has further bolstered their adoption, ensuring safety, efficacy, and quality. Overall, the patent expiration and regulatory support are key drivers propelling the adalimumab biosimilar market forward.
Adalimumab is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.
This report is a detailed and comprehensive analysis for global Adalimumab (Humira) and Biosimilar market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Adalimumab (Humira) and Biosimilar market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Adalimumab (Humira) and Biosimilar market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Adalimumab (Humira) and Biosimilar market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Adalimumab (Humira) and Biosimilar market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Adalimumab (Humira) and Biosimilar
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Adalimumab (Humira) and Biosimilar market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AbbVie, Eisai, Cadila Healthcare, Torrent Pharmaceuticals and Amgen, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Adalimumab (Humira) and Biosimilar market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Syringe
Pen
Market segment by Application
Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Other
Major players covered
AbbVie
Eisai
Cadila Healthcare
Torrent Pharmaceuticals
Amgen
Boehringer Ingelheim
Novartis
Samsung Bioepis
Viatris
Pfizer
Fresenius Kabi
Coherus
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Adalimumab (Humira) and Biosimilar product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Adalimumab (Humira) and Biosimilar, with price, sales, revenue and global market share of Adalimumab (Humira) and Biosimilar from 2018 to 2023.
Chapter 3, the Adalimumab (Humira) and Biosimilar competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Adalimumab (Humira) and Biosimilar breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Adalimumab (Humira) and Biosimilar market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Adalimumab (Humira) and Biosimilar.
Chapter 14 and 15, to describe Adalimumab (Humira) and Biosimilar sales channel, distributors, customers, research findings and conclusion.
The global Adalimumab (Humira) and Biosimilar market size was valued at USD 23070 million in 2022 and is forecast to a readjusted size of USD 16210 million by 2029 with a CAGR of -4.9% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The expiration of patents for adalimumab (Humira) has emerged as a significant driver in the biosimilar market. Adalimumab is a widely used biologic medication for autoimmune diseases. The patent expiry allows for the entry of biosimilar versions of Humira, which are highly similar and offer a more cost-effective alternative. This increased competition fosters price reduction and improved accessibility for patients, addressing the growing demand for affordable treatments. Furthermore, regulatory support for biosimilars has further bolstered their adoption, ensuring safety, efficacy, and quality. Overall, the patent expiration and regulatory support are key drivers propelling the adalimumab biosimilar market forward.
Adalimumab is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.
This report is a detailed and comprehensive analysis for global Adalimumab (Humira) and Biosimilar market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Adalimumab (Humira) and Biosimilar market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Adalimumab (Humira) and Biosimilar market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Adalimumab (Humira) and Biosimilar market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Adalimumab (Humira) and Biosimilar market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Adalimumab (Humira) and Biosimilar
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Adalimumab (Humira) and Biosimilar market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AbbVie, Eisai, Cadila Healthcare, Torrent Pharmaceuticals and Amgen, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Adalimumab (Humira) and Biosimilar market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Syringe
Pen
Market segment by Application
Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Other
Major players covered
AbbVie
Eisai
Cadila Healthcare
Torrent Pharmaceuticals
Amgen
Boehringer Ingelheim
Novartis
Samsung Bioepis
Viatris
Pfizer
Fresenius Kabi
Coherus
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Adalimumab (Humira) and Biosimilar product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Adalimumab (Humira) and Biosimilar, with price, sales, revenue and global market share of Adalimumab (Humira) and Biosimilar from 2018 to 2023.
Chapter 3, the Adalimumab (Humira) and Biosimilar competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Adalimumab (Humira) and Biosimilar breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Adalimumab (Humira) and Biosimilar market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Adalimumab (Humira) and Biosimilar.
Chapter 14 and 15, to describe Adalimumab (Humira) and Biosimilar sales channel, distributors, customers, research findings and conclusion.
Index1 Market Overview
1.1 Product Overview and Scope of Adalimumab (Humira) and Biosimilar
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Adalimumab (Humira) and Biosimilar Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Syringe
1.3.3 Pen
1.4 Market Analysis by Application
1.4.1 Overview: Global Adalimumab (Humira) and Biosimilar Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Ankylosing Spondylitis
1.4.3 Rheumatoid Arthritis
1.4.4 Crohn’s Disease
1.4.5 Other
1.5 Global Adalimumab (Humira) and Biosimilar Market Size & Forecast
1.5.1 Global Adalimumab (Humira) and Biosimilar Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Adalimumab (Humira) and Biosimilar Sales Quantity (2018-2029)
1.5.3 Global Adalimumab (Humira) and Biosimilar Average Price (2018-2029)
2 Manufacturers Profiles
2.1 AbbVie
2.1.1 AbbVie Details
2.1.2 AbbVie Major Business
2.1.3 AbbVie Adalimumab (Humira) and Biosimilar Product and Services
2.1.4 AbbVie Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 AbbVie Recent Developments/Updates
2.2 Eisai
2.2.1 Eisai Details
2.2.2 Eisai Major Business
2.2.3 Eisai Adalimumab (Humira) and Biosimilar Product and Services
2.2.4 Eisai Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Eisai Recent Developments/Updates
2.3 Cadila Healthcare
2.3.1 Cadila Healthcare Details
2.3.2 Cadila Healthcare Major Business
2.3.3 Cadila Healthcare Adalimumab (Humira) and Biosimilar Product and Services
2.3.4 Cadila Healthcare Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Cadila Healthcare Recent Developments/Updates
2.4 Torrent Pharmaceuticals
2.4.1 Torrent Pharmaceuticals Details
2.4.2 Torrent Pharmaceuticals Major Business
2.4.3 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Product and Services
2.4.4 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Torrent Pharmaceuticals Recent Developments/Updates
2.5 Amgen
2.5.1 Amgen Details
2.5.2 Amgen Major Business
2.5.3 Amgen Adalimumab (Humira) and Biosimilar Product and Services
2.5.4 Amgen Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Amgen Recent Developments/Updates
2.6 Boehringer Ingelheim
2.6.1 Boehringer Ingelheim Details
2.6.2 Boehringer Ingelheim Major Business
2.6.3 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Product and Services
2.6.4 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Boehringer Ingelheim Recent Developments/Updates
2.7 Novartis
2.7.1 Novartis Details
2.7.2 Novartis Major Business
2.7.3 Novartis Adalimumab (Humira) and Biosimilar Product and Services
2.7.4 Novartis Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Novartis Recent Developments/Updates
2.8 Samsung Bioepis
2.8.1 Samsung Bioepis Details
2.8.2 Samsung Bioepis Major Business
2.8.3 Samsung Bioepis Adalimumab (Humira) and Biosimilar Product and Services
2.8.4 Samsung Bioepis Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Samsung Bioepis Recent Developments/Updates
2.9 Viatris
2.9.1 Viatris Details
2.9.2 Viatris Major Business
2.9.3 Viatris Adalimumab (Humira) and Biosimilar Product and Services
2.9.4 Viatris Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Viatris Recent Developments/Updates
2.10 Pfizer
2.10.1 Pfizer Details
2.10.2 Pfizer Major Business
2.10.3 Pfizer Adalimumab (Humira) and Biosimilar Product and Services
2.10.4 Pfizer Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Pfizer Recent Developments/Updates
2.11 Fresenius Kabi
2.11.1 Fresenius Kabi Details
2.11.2 Fresenius Kabi Major Business
2.11.3 Fresenius Kabi Adalimumab (Humira) and Biosimilar Product and Services
2.11.4 Fresenius Kabi Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Fresenius Kabi Recent Developments/Updates
2.12 Coherus
2.12.1 Coherus Details
2.12.2 Coherus Major Business
2.12.3 Coherus Adalimumab (Humira) and Biosimilar Product and Services
2.12.4 Coherus Adalimumab (Humira) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Coherus Recent Developments/Updates
3 Competitive Environment: Adalimumab (Humira) and Biosimilar by Manufacturer
3.1 Global Adalimumab (Humira) and Biosimilar Sales Quantity by Manufacturer (2018-2023)
3.2 Global Adalimumab (Humira) and Biosimilar Revenue by Manufacturer (2018-2023)
3.3 Global Adalimumab (Humira) and Biosimilar Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Adalimumab (Humira) and Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Adalimumab (Humira) and Biosimilar Manufacturer Market Share in 2022
3.4.2 Top 6 Adalimumab (Humira) and Biosimilar Manufacturer Market Share in 2022
3.5 Adalimumab (Humira) and Biosimilar Market: Overall Company Footprint Analysis
3.5.1 Adalimumab (Humira) and Biosimilar Market: Region Footprint
3.5.2 Adalimumab (Humira) and Biosimilar Market: Company Product Type Footprint
3.5.3 Adalimumab (Humira) and Biosimilar Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Adalimumab (Humira) and Biosimilar Market Size by Region
4.1.1 Global Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2018-2029)
4.1.2 Global Adalimumab (Humira) and Biosimilar Consumption Value by Region (2018-2029)
4.1.3 Global Adalimumab (Humira) and Biosimilar Average Price by Region (2018-2029)
4.2 North America Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029)
4.3 Europe Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029)
4.4 Asia-Pacific Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029)
4.5 South America Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029)
4.6 Middle East and Africa Adalimumab (Humira) and Biosimilar Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)
5.2 Global Adalimumab (Humira) and Biosimilar Consumption Value by Type (2018-2029)
5.3 Global Adalimumab (Humira) and Biosimilar Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)
6.2 Global Adalimumab (Humira) and Biosimilar Consumption Value by Application (2018-2029)
6.3 Global Adalimumab (Humira) and Biosimilar Average Price by Application (2018-2029)
7 North America
7.1 North America Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)
7.2 North America Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)
7.3 North America Adalimumab (Humira) and Biosimilar Market Size by Country
7.3.1 North America Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2029)
7.3.2 North America Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)
8.2 Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)
8.3 Europe Adalimumab (Humira) and Biosimilar Market Size by Country
8.3.1 Europe Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2029)
8.3.2 Europe Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Adalimumab (Humira) and Biosimilar Market Size by Region
9.3.1 Asia-Pacific Adalimumab (Humira) and Biosimilar Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Adalimumab (Humira) and Biosimilar Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)
10.2 South America Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)
10.3 South America Adalimumab (Humira) and Biosimilar Market Size by Country
10.3.1 South America Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2029)
10.3.2 South America Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Adalimumab (Humira) and Biosimilar Market Size by Country
11.3.1 Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Adalimumab (Humira) and Biosimilar Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Adalimumab (Humira) and Biosimilar Market Drivers
12.2 Adalimumab (Humira) and Biosimilar Market Restraints
12.3 Adalimumab (Humira) and Biosimilar Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Adalimumab (Humira) and Biosimilar and Key Manufacturers
13.2 Manufacturing Costs Percentage of Adalimumab (Humira) and Biosimilar
13.3 Adalimumab (Humira) and Biosimilar Production Process
13.4 Adalimumab (Humira) and Biosimilar Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Adalimumab (Humira) and Biosimilar Typical Distributors
14.3 Adalimumab (Humira) and Biosimilar Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Published By : GlobalInfoResearch
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
